CIK 0001661998 · Non-accelerated filer<br>Smaller reporting company
Q32 Bio Inc.
Sign in to watch- Ticker
- QTTB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 473468154
- Phone
- 781-999-0232
- Business address
- 830 WINTER STREET, WALTHAM, MA, 02451
- Former names
- Q32 Bio Inc., Homology Medicines, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $320,396
- in 6 filings
Net −$320,396. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-12 | Iwicki Mark T Director | Grant or award · Stock Option (Right to Buy) | +9,810 | 9,810 | ||
| 2026-06-12 | Manke Isaac Director | Grant or award · Stock Option (Right to Buy) | +9,810 | 9,810 | ||
| 2026-06-12 | TZIANABOS ARTHUR Director | Grant or award · Stock Option (Right to Buy) | +9,810 | 9,810 | ||
| 2026-06-12 | GRAYZEL DAVID S. Director | Grant or award · Stock Option (Right to Buy) | +9,810 | 9,810 | ||
| 2026-06-12 | Thistle Mary Director | Grant or award · Stock Option (Right to Buy) | +9,810 | 9,810 | ||
| 2026-06-12 | Xu Diyong Director | Grant or award · Stock Option (Right to Buy) | +9,810 | 9,810 | ||
| 2026-06-12 | Lundberg Sven Ante Director | Grant or award · Stock Option (Right to Buy) | +9,810 | 9,810 | ||
| 2026-05-28 | Xu Diyong Director | Purchase | +1,250,000 | $8.00 | $10.0M | 3,502,987 |
| 2026-05-28 | Xu Diyong Director | Purchase | +625,000 | $8.00 | $5.0M | 625,000 |
| 2026-05-28 | ORBIMED ADVISORS LLC Director | Purchase | +1,250,000 | $8.00 | $10.0M | 3,502,987 |
| 2026-05-28 | ORBIMED ADVISORS LLC Director | Purchase | +625,000 | $8.00 | $5.0M | 625,000 |
| 2026-02-25 | Kalowski Lee CFO and President | Sale | −3,995 | $4.51 | $18K | 35,943 |
| 2026-02-25 | Morrison Jodie Pope CEO | Sale | −9,896 | $4.51 | $45K | 89,104 |
| 2026-02-25 | Violette Shelia M. Chief Scientific Officer | Sale | −2,815 | $4.51 | $13K | 55,569 |
| 2026-02-24 | Violette Shelia M. Chief Scientific Officer | Grant or award | +37,500 | 93,069 | ||
| 2026-02-24 | Morrison Jodie Pope CEO | Grant or award | +132,000 | 221,104 | ||
| 2026-02-24 | Kalowski Lee CFO and President | Grant or award | +53,250 | 89,193 | ||
| 2026-01-15 | LAPORTE KATHLEEN Director | Grant or award · Stock Option (Right to Buy) | +23,272 | $2.75 | $64K | 23,272 |
| 2026-01-15 | GRAYZEL DAVID S. Director | Grant or award · Stock Option (Right to Buy) | +16,363 | $2.75 | $45K | 16,363 |
| 2026-01-15 | Lundberg Sven Ante Director | Grant or award · Stock Option (Right to Buy) | +20,363 | $2.75 | $56K | 20,363 |
Page 2 of 11 · 207 trades